Last reviewed 2026-05-31 · How we verify

[14C]AZD0780 Solution for Infusion

AstraZeneca · Phase 1 active Small molecule ✓ Verified May 2026 Quality 0/100

[14C]AZD0780 Solution for Infusion is a Small molecule drug developed by AstraZeneca. It is currently in Phase 1 development. Also known as: [14C]AZD0780.

[14C]AZD0780 Solution for Infusion is an oligosaccharide modality, specifically an anticoagulant heparin solution. It is used to prevent blood clotting.

Likelihood of approval

12.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
AstraZeneca is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	[14C]AZD0780 Solution for Infusion
Also known as	[14C]AZD0780
Sponsor	AstraZeneca
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[14C]AZD0780 Solution for Infusion CI brief — competitive landscape report
[14C]AZD0780 Solution for Infusion updates RSS · CI watch RSS
AstraZeneca portfolio CI

Frequently asked questions about [14C]AZD0780 Solution for Infusion

What is [14C]AZD0780 Solution for Infusion?

[14C]AZD0780 Solution for Infusion is a Small molecule drug developed by AstraZeneca.

Who makes [14C]AZD0780 Solution for Infusion?

[14C]AZD0780 Solution for Infusion is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

Is [14C]AZD0780 Solution for Infusion also known as anything else?

[14C]AZD0780 Solution for Infusion is also known as [14C]AZD0780.

What development phase is [14C]AZD0780 Solution for Infusion in?

[14C]AZD0780 Solution for Infusion is in Phase 1.

Manufacturer: AstraZeneca — full pipeline
Also known as: [14C]AZD0780

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing